Ms. Ullstrup has over twenty-five years of experience in substance use and mental health treatment for women. She has been on the Meta House staff since 1995 and was a recipient of their services in 1994. Over her career at Meta House, she has held many different positions within their full continuum of care. Most recently as the VP of Clinical Services where she provided leadership and oversight for all three of Meta House Programs: Residential, Outpatient, and Recovery Housing Community. She was responsible for the vision and goals and coordination of services across all programs. She developed policies and procedures to implement grants, certification, and licensing requirements. In 2010, under her leadership, Meta House became a smoke free campus and formally began treating nicotine addiction.
As of June of 2023, Ms. Ullstrup has stepped down from her leadership role to Special Projects Advisor to assist Meta House with its strategic growth plan.
Dr. Pamela Valera is an Assistant Professor in the Department of Urban-Global Public Health and serves as the Ph.D. Director at the School of Public Health, Rutgers University, the State University of New Jersey. She received a Bachelor of Arts Degree in Psychology from the University of San Francisco, an MSW from the University of Michigan, and a PhD., in Social Work from the University of South Carolina. In addition to her academic background, Dr. Valera has completed a three-year NIMH T32 postdoctoral research fellowship in HIV Prevention and Human Sexuality at the Columbia University/New York Psychiatric Institute, as well as clinical training in cancer health from the Albert Einstein College of Medicine, and also an NHLBI R25 Program to Increase Diversity among Individuals Engaged in Health-Related Research (PRIDE) fellowship from SUNY Downstate Medical Center.
Dr. Valera’s research focuses on the drivers of health inequities in marginalized groups, including people living with HIV, those at risk for HIV, and people involved in the criminal justice system). At Rutgers School of Public Health, she developed the Community Health Justice Lab (http://www.chjl.org), where members address inequity in health promotion activities among medically underserved and hidden populations. Dr. Valera uses the social determinants of health lens to explore health behaviors and health promotion strategies to reduce the detrimental effects of incarceration.
- List two risk factors for tobacco use in the justice involved population.
- Describe two promising and evidence-based practices to address tobacco use disorders (TUD) among individuals in the criminal justice system.
- Identify two systemic barriers and challenges to integrating TUD treatment within the criminal justice system.
- Discuss two recommendations to address TUD treatment integration within the criminal justice system, with a focus on steps to overcome systemic barriers, and implement policies, procedures, and best practices to improve access to TUD treatment.
CME/CE credit is no longer available for this live activity. Credit will be available for the recorded version of this activity in September.
Certificates of Attendance
Click here to generate a certificate of attendance for participating on this webinar.
The University of California, San Francisco (UCSF) School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
UCSF designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the webinar activity.
Advance Practice Registered Nurses and Registered Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 CreditTM issued by organizations accredited by the ACCME.
Physician Assistants: The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 CreditTM are acceptable for continuing medical education requirements for recertification.
California Pharmacists: The California Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved for AMA PRA category 1 CreditTM. If you are a pharmacist in another state, you should check with your state board for approval of this credit.
California Psychologists: The California Board of Psychology recognizes and accepts for continuing education credit courses that are provided by entities approved by the Accreditation Council for Continuing Medical Education (ACCME). AMA PRA Category 1 CreditTM is acceptable to meeting the CE requirements for the California Board of Psychology. Providers in other states should check with their state boards for acceptance of CME credit.
California Behavioral Science Professionals: University of California, San Francisco School of Medicine (UCSF) is approved by the California Association of Marriage and Family Therapists to sponsor continuing education for behavioral health providers. UCSF maintains responsibility for this program/course and its content.
Course meets the qualifications for 1.0 hour of continuing education credit for LMFTs, LCSWs, LPCCs, and/or LEPs as required by the California Board of Behavioral Sciences. Provider # 64239.
ACCREDITATION FOR CALIFORNIA ADDICTION COUNSELORS
The UCSF office of continuing medical education is accredited by the California Consortium of Addiction Programs and Professionals (CCAPP), to provide continuing education credit for California addiction counselors. UCSF designates this live, virtual activity, for a maximum of 1.0 CCAPP credit. Addiction counselors should claim only the credit commensurate with the extent of their participation in the activity. Provider number: 7-20-322-0724.
This UCSF CME activity was planned and developed to uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.
All speakers, planning committee members and reviewers have disclosed they have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Catherine Bonniot, Anita Browning, Christine Cheng, Brian Clark, Allison Gorrilla, MPH, Kerry Cork, JD, Jennifer Matekuare, Chad Morris, PhD, Ma Krisanta Pamatmat, MPH, Jessica Safier, MA, Christine Ullstrup, LCSW, Pamela Valera, PhD, and Maya Vijayaraghavan, MD, MAS.